Associated tags: PLC, Information services, Clarivate, Intelligence, CLVT, NYSE, Research
Locations: SWITZERLAND, CANADA, FRANCE, ITALY, SOUTH KOREA, INDIA, CALIFORNIA, NEW MEXICO, ILLINOIS, INDIANA, MASSACHUSETTS, RUSSIA, SOUTH AFRICA, INDONESIA, SAUDI ARABIA, NETHERLANDS, MISSOURI, MISSISSIPPI, AETNA, NEW JERSEY, KANSAS, NEBRASKA, SOUTH CAROLINA, TEXAS, DELAWARE, COLORADO, DERWENT, DISCO, GE, SWEDEN, HONDA, SILICON VALLEY, UNITED KINGDOM, LONDON, NORTH AMERICA, ENGLAND, LATIN AMERICA, ARGENTINA, BRAZIL, ECUADOR, CHILE, PERU, COLOMBIA, MEXICO, STONEWALL, CHINA, CAR, VIRGINIA
LONDON, May 9, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that OMRON has selected IPfolio™, an intellectual property management software from Clarivate to transform their IP operations. This solution will enable OMRON, a leading automation company to make smarter decisions and plan strategically using IP data and analytical insights.
Key Points:
- LONDON, May 9, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that OMRON has selected IPfolio™, an intellectual property management software from Clarivate to transform their IP operations.
- This solution will enable OMRON, a leading automation company to make smarter decisions and plan strategically using IP data and analytical insights.
- The IP team at OMRON can enhance their analysis and collaboration with stakeholders by using insightful data visualizations.
- We are confident that IPfolio will help OMRON simplify the process of managing IP assets across the entire lifecycle."
LONDON, May 9, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that OMRON has selected IPfolio™, an intellectual property management software from Clarivate to transform their IP operations. This solution will enable OMRON, a leading automation company to make smarter decisions and plan strategically using IP data and analytical insights.
Key Points:
- LONDON, May 9, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that OMRON has selected IPfolio™, an intellectual property management software from Clarivate to transform their IP operations.
- This solution will enable OMRON, a leading automation company to make smarter decisions and plan strategically using IP data and analytical insights.
- The IP team at OMRON can enhance their analysis and collaboration with stakeholders by using insightful data visualizations.
- We are confident that IPfolio will help OMRON simplify the process of managing IP assets across the entire lifecycle."
LONDON, May 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024.
Key Points:
- (2) Adjusted diluted EPS for 2024 is calculated based on approximately 730 million fully diluted weighted average ordinary shares outstanding.
- Clarivate will host a conference call and webcast today to review the results for the first quarter at 9:00 a.m. Eastern Time.
- As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.
- Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results.
LONDON, May 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024.
Key Points:
- (2) Adjusted diluted EPS for 2024 is calculated based on approximately 730 million fully diluted weighted average ordinary shares outstanding.
- Clarivate will host a conference call and webcast today to review the results for the first quarter at 9:00 a.m. Eastern Time.
- As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.
- Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results.
LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
Key Points:
- Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis
LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™ .
- It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
- Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population.
- Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform.
LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
Key Points:
- Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis
LONDON, May 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™ .
- It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
- Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population.
- Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform.
LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions.
Key Points:
- LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence ™ solution, featuring a new post-approval variations module.
- The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking.
- Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information.
- With its new module covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics.
LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions.
Key Points:
- LONDON, May 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence ™ solution, featuring a new post-approval variations module.
- The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking.
- Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information.
- With its new module covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics.
LONDON, May 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
Key Points:
- LONDON, May 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
- If such VWAP is (i) greater than $31.20, then the mandatory conversion rate will be 3.2052 ordinary shares of Clarivate per Preferred Share, (ii) less than or equal to $31.20 but equal to or greater than $26.00, then the mandatory conversion rate will be a number of ordinary shares of Clarivate per Preferred Share equal to $100.00 divided by such VWAP and (iii) less than $26.00, then the mandatory conversion rate will be 3.8462 ordinary shares of Clarivate per Preferred Share.
- The mandatory conversion rate will be announced following the end of the valuation period.
- The above description of the terms of the Preferred Shares is not complete and is subject to, and qualified in its entirety by reference to, the "Statement of Rights" for the Preferred Shares, which is filed as Exhibit 3.2 to Clarivate's annual report on Form 10-K for the fiscal year ended December 31, 2023.
LONDON, May 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
Key Points:
- LONDON, May 1, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT; CLVT PR A) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the "Preferred Shares"), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
- If such VWAP is (i) greater than $31.20, then the mandatory conversion rate will be 3.2052 ordinary shares of Clarivate per Preferred Share, (ii) less than or equal to $31.20 but equal to or greater than $26.00, then the mandatory conversion rate will be a number of ordinary shares of Clarivate per Preferred Share equal to $100.00 divided by such VWAP and (iii) less than $26.00, then the mandatory conversion rate will be 3.8462 ordinary shares of Clarivate per Preferred Share.
- The mandatory conversion rate will be announced following the end of the valuation period.
- The above description of the terms of the Preferred Shares is not complete and is subject to, and qualified in its entirety by reference to, the "Statement of Rights" for the Preferred Shares, which is filed as Exhibit 3.2 to Clarivate's annual report on Form 10-K for the fiscal year ended December 31, 2023.
